Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 17/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 17/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 16/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 16/20 | 1.00 |
| ▸ | GCGR | P47871 | 15/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 12/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 0.79 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.79 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.79 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.79 |
| ▸ | FRK | P42685 | 4/20 | 0.79 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.79 |
| ▸ | GSK3B | P49841 | 4/20 | 0.79 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.79 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.79 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.79 |
| ▸ | RAF1 | P04049 | 3/20 | 0.79 |
| ▸ | PRKACA | P17612 | 3/20 | 0.70 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11082212 | 0.93 | MAPK13 (0.87) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL15075611 | 0.93 | MAPK13 (0.89) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL15075603 | 0.89 | MAPK11 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL19868925 | 0.89 | MAPK11 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL19952909 | 0.88 | MAPK13 (0.78) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6469341 | 0.88 | MAPK13 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6164173 | 0.87 | MAPK13 (0.79) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6469323 | 0.87 | MAPK13 (0.79) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6452661 | 0.87 | MAPK14 (0.76) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL13497841 | 0.86 | MAPK11 (0.76) | MAPK11MAPK14MAPK13MAPK12GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | claimed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | claimed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | claimed |
| EP-0889887-A4 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORP (US) | 2003-06-11 | — | — | EP | claimed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | claimed |
| EP-0959885-A4 | TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE | MERCK & CO INC (US) | 2002-07-17 | — | — | EP | claimed |
| US-6288089-B1 | ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-11 | — | — | US | claimed |
| US-6235760-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2001-05-22 | — | — | US | claimed |
| EP-0906099-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | claimed |
| EP-0959885-A1 | TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE | Merck & Co., Inc. (US) | 1999-12-01 | — | — | EP | claimed |
| EP-0906099-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-04-07 | — | — | EP | claimed |
| EP-0889887-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | claimed |
| WO-1998022108-A1 | TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE | MERCK & CO., INC. (US) | 1998-05-28 | — | — | WO | claimed |
| WO-1997036587-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | claimed |
| WO-1997035855-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-02 | — | — | WO | claimed |
| US-20240000821-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | UNIV JOHNS HOPKINS (US) | 2024-01-04 | — | — | US | disclosed |
| US-20200078387-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY | 2020-03-12 | — | — | US | disclosed |
| WO-1995003297-A1 | IMIDAZOLES FOR TREATING CYTOKINE MEDIATED DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-02 | — | — | WO | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | CSNK1G1, CSNK1E, CSNK1D | MAPK11 1215/4885MAPK14 662/4885MAPK13 456/4885 |
| US-20030064997-A1 | Novel compounds | BRD4, BRDT, HDAC6 | MAPK11 2198/4885MAPK14 3769/4885MAPK13 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.